Movement Alert｜Corcept Therapeutics Falls 5.04% in Regular Trading, Profit-Taking After Prior Session Earnings-Driven Surge Amid Broad Pharma Weakness

Market Focus07-31

On July 31, Corcept Therapeutics declined 5.04% in regular trading, trading at $112.445/share, with turnover of $44.99 million. The pullback follows the stock's approximately 16% surge in the prior session after delivering a blowout Q2 earnings report.

The company reported Q2 EPS of $0.36, vastly exceeding the consensus estimate of $0.02, while revenue of $256.1 million surpassed expectations of $221.1 million by approximately 16%. The company also raised full-year revenue guidance to $1.1-$1.2 billion from its prior range of $950 million to $1.05 billion, well above the FactSet estimate of $999.5 million. The strong results were driven by core product Korlym and newly approved drug Lifyorli commercialization progress. Additionally, Canaccord Genuity raised its target price from $135 to $150.

Despite the strong fundamental backdrop, broader pharma sector weakness weighed on sentiment, with Novo-Nordisk falling 8.91%, Eli Lilly declining 2.01%, and Bristol-Myers Squibb down 1.43%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1163426208?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 22:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163426208","market":"us","top_or_hot":-1,"title":"Movement Alert｜Corcept Therapeutics Falls 5.04% in Regular Trading, Profit-Taking After Prior Session Earnings-Driven Surge Amid Broad Pharma Weakness","media":"Market Focus","content":"<p><p>On July 31, Corcept Therapeutics declined 5.04% in regular trading, trading at $112.445/share, with turnover of $44.99 million. The pullback follows the stock's approximately 16% surge in the prior session after delivering a blowout Q2 earnings report.</p><p>The company reported Q2 EPS of $0.36, vastly exceeding the consensus estimate of $0.02, while revenue of $256.1 million surpassed expectations of $221.1 million by approximately 16%. The company also raised full-year revenue guidance to $1.1-$1.2 billion from its prior range of $950 million to $1.05 billion, well above the FactSet estimate of $999.5 million. The strong results were driven by core product Korlym and newly approved drug Lifyorli commercialization progress. Additionally, Canaccord Genuity raised its target price from $135 to $150.</p><p>Despite the strong fundamental backdrop, broader pharma sector weakness weighed on sentiment, with Novo-Nordisk falling 8.91%, Eli Lilly declining 2.01%, and Bristol-Myers Squibb down 1.43%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Corcept Therapeutics Falls 5.04% in Regular Trading, Profit-Taking After Prior Session Earnings-Driven Surge Amid Broad Pharma Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Corcept Therapeutics Falls 5.04% in Regular Trading, Profit-Taking After Prior Session Earnings-Driven Surge Amid Broad Pharma Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-31 22:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 31, Corcept Therapeutics declined 5.04% in regular trading, trading at $112.445/share, with turnover of $44.99 million. The pullback follows the stock's approximately 16% surge in the prior session after delivering a blowout Q2 earnings report.</p><p>The company reported Q2 EPS of $0.36, vastly exceeding the consensus estimate of $0.02, while revenue of $256.1 million surpassed expectations of $221.1 million by approximately 16%. The company also raised full-year revenue guidance to $1.1-$1.2 billion from its prior range of $950 million to $1.05 billion, well above the FactSet estimate of $999.5 million. The strong results were driven by core product Korlym and newly approved drug Lifyorli commercialization progress. Additionally, Canaccord Genuity raised its target price from $135 to $150.</p><p>Despite the strong fundamental backdrop, broader pharma sector weakness weighed on sentiment, with Novo-Nordisk falling 8.91%, Eli Lilly declining 2.01%, and Bristol-Myers Squibb down 1.43%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CORT","symbol_name":"Corcept医疗","start_time":0,"source_url":"","article_id":"1163426208","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163426208","pubTimestamp":1785509932,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 31, Corcept Therapeutics declined 5.04% in regular trading, trading at $112.445/share, with turnover of $44.99 million. The pullback follows the stock's approximately 16% surge in the prior...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CORT":"Corcept医疗"},"translate_title":"走势警报|Corcept Therapeutics 在常规交易中下跌 5.04%，在制药行业普遍疲软的情况下，前一交易日盈利推动飙升后获利了结","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":1},"content_text":"On July 31, Corcept Therapeutics declined 5.04% in regular trading, trading at $112.445/share, with turnover of $44.99 million. The pullback follows the stock's approximately 16% surge in the prior session after delivering a blowout Q2 earnings report.The company reported Q2 EPS of $0.36, vastly exceeding the consensus estimate of $0.02, while revenue of $256.1 million surpassed expectations of $221.1 million by approximately 16%. The company also raised full-year revenue guidance to $1.1-$1.2 billion from its prior range of $950 million to $1.05 billion, well above the FactSet estimate of $999.5 million. The strong results were driven by core product Korlym and newly approved drug Lifyorli commercialization progress. Additionally, Canaccord Genuity raised its target price from $135 to $150.Despite the strong fundamental backdrop, broader pharma sector weakness weighed on sentiment, with Novo-Nordisk falling 8.91%, Eli Lilly declining 2.01%, and Bristol-Myers Squibb down 1.43%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163426208","isCrawlerRequest":true}